ACTUATE THERAPEUTICS, INC.
ACTUDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
17dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ruxolitinib | Phase 2 | Myelofibrosis | - | Patent 2041 |
9-ING-41 | Phase 2 | Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ACTUATE THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in ACTUATE THERAPEUTICS, INC.'s (ACTU) pipeline across Phase 2. Its lead program is Ruxolitinib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACTUATE THERAPEUTICS, INC.'s next FDA catalyst?→
ACTUATE THERAPEUTICS, INC.'s (ACTU) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACTU biotech catalysts?→
Add ACTU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACTUATE THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.